Clinical Trial Update: Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy [Phase 3]

View source ↗

Summary

A completed Phase 3 trial evaluating the safety and efficacy of everolimus in combination with cyclosporine (Neoral) in adult heart transplant recipients with e…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiac Allograft Vasculopathy
• Graft Rejection

Drugs mentioned

• Everolimus (everolimus)
• NEORAL (CYCLOSPORINE)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Graft Rejection | Phase 3 | Status: COMPLETED